<p>PureTech Health（納斯達克代碼：PRTC - 獲取免費報告）於週三發佈了其財報。該公司報告本季度每股收益為（$1.35），超出市場共識預期的（$1.94）$0.59，FiscalAI 報道。該公司本季度的收入為 140 萬美元，而分析師預期為 190 萬美元。</p>
<p>獲取 <strong>PureTech Health</strong> 的提醒：</p>
<p>以下是來自 PureTech Health 電話會議的關鍵要點：</p>
<ul>
<li>PureTech 制定了精簡的戰略，計劃自願從納斯達克退市以降低成本，提前啓動創辦實體以利用外部資本，並增加對股東的資本回報。</li>
<li><strong>Celea Therapeutics</strong> 的融資被描述為 “基本完成”，預計在 2026 年第三季度初完成，以支持 deupirfenidone 的 III 期 SURPASS‑IPF 試驗，這是 PureTech 的一個近期價值轉折點。</li>
<li><strong>Gallop</strong> 的 LYT‑200 報告了積極的 I-B 期頂線數據（12 mg/kg 劑量，良好的安全性，劑量依賴性活性），促使其優先考慮複發性難治高風險 MDS，並計劃與 FDA 接洽進行潛在的註冊試驗，同時尋求外部資本。</li>
<li>截至 2026 年 3 月 31 日，PureTech 擁有約 <strong>2.481 億美元</strong> 的現金及現金等價物，並預計運營資金至少可持續到 2028 年底，包括預計參與 Celea 和 Gallop 的融資。</li>
<li>創新引擎將遵循 LIFE 模型，以適度的資本推進概念階段的項目，目標是在未來三年內開發最多兩個候選藥物（重點領域包括中樞神經系統和資本效率高的小分子）。</li>
</ul>
<h2>PureTech Health 股價下跌 4.9%</h2>
<p>週三中午交易時，納斯達克：PRTC 股價下跌 0.89 美元，跌至 17.25 美元。該公司的交易量為 13,352 股，而其平均交易量為 4,447 股。該公司的 50 日簡單移動平均為 16.87 美元，200 日簡單移動平均為 17.25 美元。PureTech Health 的一年低點為 14.50 美元，一年高點為 19.92 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>另外，Weiss Ratings 在 4 月 21 日的研究報告中重申了對 PureTech Health 股票的 “賣出（d）” 評級。一位分析師對該股票給予了賣出評級，根據 MarketBeat 的數據，該股票目前的平均評級為 “賣出”。</p>
<p><strong>獲取我們最新的 PureTech Health 股票分析</strong></p>
<h2>機構資金流入和流出</h2>
<p>一家機構投資者最近增加了在 PureTech Health 股票中的持倉。Pentwater Capital Management LP 在第三季度將其在 PureTech Health PLC 贊助的 ADR（納斯達克：PRTC - 免費報告）中的持股提高了 50.0%，根據該公司最近向 SEC 提交的 13F 表格。該基金在本季度額外購買了 25,000 股後，持有 75,000 股該公司的股票。Pentwater Capital Management LP 在其最近向 SEC 提交的文件中持有的 PureTech Health 股票價值為 1,388,000 美元。對沖基金和其他機構投資者持有該公司 0.04% 的股票。</p>
<h2>關於 PureTech Health</h2>
<p>（獲取免費報告）</p>
<p>PureTech Health（納斯達克：PRTC）是一家臨牀階段的生物治療公司，專注於創造和開發一流的藥物，涵蓋免疫學、炎症、腫瘤學和神經科學。該公司通過在內部孵化項目並將選定資產推進為獨立的、創造價值的實體來運營。其內部管道包括多個針對纖維化疾病、實體腫瘤和罕見遺傳疾病的臨牀和臨牀前候選藥物。</p>
<p>PureTech 的專有平台技術涵蓋單克隆抗體、小分子和細胞治療等多種形式。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票超過 PureTech Health</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 PureTech Health 嗎？</h2>
<p>在你考慮 PureTech Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 PureTech Health 並不在名單上。</p>
<p>雖然 PureTech Health 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PRTC

PRTCY

<p>PureTech Health（納斯達克代碼：PRTC）報告的季度每股收益為（$1.35），超出預期的（$1.94）$0.59。收入為 140 萬美元，低於預期的 190 萬美元。該公司計劃從納斯達克退市以降低成本，並旨在更早推出實體以實現資本槓桿。PureTech 擁有 2.481 億美元的現金，確保其運營資金可持續到 2028 年。儘管股價下跌 4.9% 至 17.25 美元，分析師仍維持 “賣出” 評級，機構投資者則增加了持股。PureTech 專注於在多個治療領域開發首創藥物</p>

<p>PureTech Health (NASDAQ:PRTC - Get Free Report) issued its earnings results on Wednesday. The company reported ($1.35) earnings per share for the quarter, topping the consensus estimate of ($1.94) by $0.59, FiscalAI reports. The firm had revenue of $1.40 million during the quarter, compared to analysts' expectations of $1.90 million.</p>
<div class="lb-trans"><p>PureTech Health（納斯達克代碼：PRTC - 獲取免費報告）於週三發佈了其財報。該公司報告本季度每股收益為（$1.35），超出市場共識預期的（$1.94）$0.59，FiscalAI 報道。該公司本季度的收入為 140 萬美元，而分析師預期為 190 萬美元。</p>
</div><p>Get <strong>PureTech Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>PureTech Health</strong> 的提醒：</p>
</div><p>Here are the key takeaways from PureTech Health's conference call:</p>
<div class="lb-trans"><p>以下是來自 PureTech Health 電話會議的關鍵要點：</p>
</div><ul>
<li>PureTech has a refined strategy to operate a <strong>leaner hub</strong>, voluntarily delist from Nasdaq to reduce costs, launch founded entities earlier to leverage external capital, and increase capital returns to shareholders.</li>
<li><strong>Celea Therapeutics</strong> fundraising is described as &#34;substantially complete&#34; with a targeted close in early Q3 2026 to support a Phase III SURPASS‑IPF trial for deupirfenidone, a near‑term value inflection for PureTech.</li>
<li><strong>Gallop</strong>'s LYT‑200 reported positive Phase I‑B top‑line data (12 mg/kg dose, good safety, dose‑dependent activity), prompting prioritization of relapsed refractory high‑risk MDS and plans to engage the FDA for a potentially registration‑enabling trial while seeking external capital.</li>
<li>PureTech held approximately <strong>$248.1m</strong> in cash and equivalents as of March 31, 2026 and expects operational runway at least through the end of 2028, inclusive of anticipated participation in Celea and Gallop financings.</li>
<li>The innovation engine will follow the LIFE model to progress concept‑stage programs with modest capital, targeting up to two development candidates over the next three years (focus areas include CNS and capital‑efficient small molecules).</li>
</ul>
<div class="lb-trans"><ul>
<li>PureTech 制定了精簡的戰略，計劃自願從納斯達克退市以降低成本，提前啓動創辦實體以利用外部資本，並增加對股東的資本回報。</li>
<li><strong>Celea Therapeutics</strong> 的融資被描述為 “基本完成”，預計在 2026 年第三季度初完成，以支持 deupirfenidone 的 III 期 SURPASS‑IPF 試驗，這是 PureTech 的一個近期價值轉折點。</li>
<li><strong>Gallop</strong> 的 LYT‑200 報告了積極的 I-B 期頂線數據（12 mg/kg 劑量，良好的安全性，劑量依賴性活性），促使其優先考慮複發性難治高風險 MDS，並計劃與 FDA 接洽進行潛在的註冊試驗，同時尋求外部資本。</li>
<li>截至 2026 年 3 月 31 日，PureTech 擁有約 <strong>2.481 億美元</strong> 的現金及現金等價物，並預計運營資金至少可持續到 2028 年底，包括預計參與 Celea 和 Gallop 的融資。</li>
<li>創新引擎將遵循 LIFE 模型，以適度的資本推進概念階段的項目，目標是在未來三年內開發最多兩個候選藥物（重點領域包括中樞神經系統和資本效率高的小分子）。</li>
</ul>
</div><h2>PureTech Health Trading Down 4.9%</h2>
<div class="lb-trans"><h2>PureTech Health 股價下跌 4.9%</h2>
</div><p>NASDAQ:PRTC traded down $0.89 during mid-day trading on Wednesday, hitting $17.25. The company had a trading volume of 13,352 shares, compared to its average volume of 4,447. The business has a fifty day simple moving average of $16.87 and a 200-day simple moving average of $17.25. PureTech Health has a 1 year low of $14.50 and a 1 year high of $19.92.</p>
<div class="lb-trans"><p>週三中午交易時，納斯達克：PRTC 股價下跌 0.89 美元，跌至 17.25 美元。該公司的交易量為 13,352 股，而其平均交易量為 4,447 股。該公司的 50 日簡單移動平均為 16.87 美元，200 日簡單移動平均為 17.25 美元。PureTech Health 的一年低點為 14.50 美元，一年高點為 19.92 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (d)&#34; rating on shares of PureTech Health in a research report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 4 月 21 日的研究報告中重申了對 PureTech Health 股票的 “賣出（d）” 評級。一位分析師對該股票給予了賣出評級，根據 MarketBeat 的數據，該股票目前的平均評級為 “賣出”。</p>
</div><p><strong>Get Our Latest Stock Analysis on PureTech Health</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 PureTech Health 股票分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>An institutional investor recently raised its position in PureTech Health stock. Pentwater Capital Management LP lifted its holdings in shares of PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Free Report) by 50.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 75,000 shares of the company's stock after acquiring an additional 25,000 shares during the quarter. Pentwater Capital Management LP owned 0.31% of PureTech Health worth $1,388,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 0.04% of the company's stock.</p>
<div class="lb-trans"><p>一家機構投資者最近增加了在 PureTech Health 股票中的持倉。Pentwater Capital Management LP 在第三季度將其在 PureTech Health PLC 贊助的 ADR（納斯達克：PRTC - 免費報告）中的持股提高了 50.0%，根據該公司最近向 SEC 提交的 13F 表格。該基金在本季度額外購買了 25,000 股後，持有 75,000 股該公司的股票。Pentwater Capital Management LP 在其最近向 SEC 提交的文件中持有的 PureTech Health 股票價值為 1,388,000 美元。對沖基金和其他機構投資者持有該公司 0.04% 的股票。</p>
</div><h2>About PureTech Health</h2>
<div class="lb-trans"><h2>關於 PureTech Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>PureTech Health NASDAQ: PRTC is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.</p>
<div class="lb-trans"><p>PureTech Health（納斯達克：PRTC）是一家臨牀階段的生物治療公司，專注於創造和開發一流的藥物，涵蓋免疫學、炎症、腫瘤學和神經科學。該公司通過在內部孵化項目並將選定資產推進為獨立的、創造價值的實體來運營。其內部管道包括多個針對纖維化疾病、實體腫瘤和罕見遺傳疾病的臨牀和臨牀前候選藥物。</p>
</div><p>PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.</p>
<div class="lb-trans"><p>PureTech 的專有平台技術涵蓋單克隆抗體、小分子和細胞治療等多種形式。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than PureTech Health</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 PureTech Health</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PureTech Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 PureTech Health 嗎？</h2>
</div><p>Before you consider PureTech Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 PureTech Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 PureTech Health 並不在名單上。</p>
</div><p>While PureTech Health currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 PureTech Health 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

PureTech Health (NASDAQ:PRTC) Posts Quarterly Earnings Results, Beats Estimates By $0.59 EPS

PureTech Health（NASDAQ:PRTC）公佈季度財報，每股收益比預期高出 0.59 美元